Suggestions
Lawrence Lamb
Executive Vice President and Chief Scientific Officer at IN8bio, Inc.
Lawrence Lamb is a distinguished scientist and executive in the field of cell-based immunotherapy for cancer. He currently serves as the Executive Vice President and Chief Scientific Officer at IN8bio, a position he has held since January 2019.12
Career Highlights
Dr. Lamb's career spans over three decades in academia and industry. Prior to his current role at IN8bio, he held several notable positions:
- Professor of Medicine at the University of Alabama at Birmingham (UAB) from April 2004 to December 20181
- Director of the UAB Cell Therapy Laboratory in the Bone Marrow Transplant and Cellular Therapy department2
- Associate Professor of Pediatrics at the University of South Carolina School of Medicine from 2000 to 20041
- Assistant Professor of Medicine at the University of South Carolina School of Medicine from 1995 to 20001
Research Focus
Dr. Lamb's primary research interest is in cell-based immunotherapy for cancer. His work has been particularly influential in the study of gamma/delta T cells:
- He was the first to describe an association between gamma/delta T cell recovery and disease-free survival in allogeneic bone marrow transplantation patients1
- His current focus includes the biology of gamma/delta T cell interaction with high-grade gliomas and therapeutic gamma/delta T cell manufacturing strategies1
Education and Achievements
Dr. Lamb has an impressive educational background:
- Ph.D. and M.S. from the University of South Carolina-Columbia
- B.S. from the Medical College of Georgia
- Completed postdoctoral fellowships in Molecular Genetics and Transplantation Immunology2
In October 2020, he was honored as a Distinguished Alumnus in Biomedical Science by the University of South Carolina School of Medicine.1
Current Role
At IN8bio, Dr. Lamb leads the scientific and translational strategy as a co-founder of the company.1 He continues to be active in the field, recently discussing research and data on gamma-delta T cells and their potential in cancer immunotherapy at a conference in April 2024.3
Highlights
